Irina Antonijevic

Irina has worked in drug development for over 18 years, with a focus on translational medicine and early development in neuroscience, but also ophthalmology and immunology. She has gained experience with development of small molecules, biologics as well as nucleic acid therapeutics, in a number of global pharma and biotech organizations in the US and Europe. Before joining Triplet Therapeutics, Inc., she was VP of Translational Medicine and Development at Wave Life Sciences in Cambridge, MA, developing stereopure nucleic acid therapeutics for rare genetic diseases.

Irina has an MD from the Technical University, Munich (Germany), and a PhD in neurophysiology from the University of Edinburgh, UK. She trained in psychiatry and neurology at the Max Planck Institute of Psychiatry (in Munich), and is board certified in Germany.